145 related articles for article (PubMed ID: 10370667)
1. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao GB; Ji YY; Xu DZ; Gao J; Wu XH; Zhang QB; Hu DC
Hepatogastroenterology; 1999; 46(26):1059-64. PubMed ID: 10370667
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao G; Ji Y; Yang M; Xu D; Gao J; Wu X; Zhang Q; Hu D
Chin Med J (Engl); 1998 Oct; 111(10):922-6. PubMed ID: 11189241
[TBL] [Abstract][Full Text] [Related]
3. The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.
Kullavanuaya P; Treeprasertsuk S; Thong-Ngam D; Chaermthai K; Gonlachanvit S; Suwanagool P
J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S462-8. PubMed ID: 11529376
[TBL] [Abstract][Full Text] [Related]
4. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
5. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
6. Sustained remission and viraemia in chronic hepatitis C treated with recombinant alpha-interferon (rIFN-alpha).
Bresci G; Gambardella L; Parisi G; Banti S; Scatena F; Bertoni M; Capria A
Int J Clin Pharmacol Res; 1995; 15(5-6):175-9. PubMed ID: 8835615
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.
Tabaru A; Narita R; Hiura M; Abe S; Otsuki M
Am J Gastroenterol; 2005 Apr; 100(4):862-7. PubMed ID: 15784033
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.
Sarin SK; Goyal A; Kumar S; Guptan RC; Hashmi AZ; Sakhuja P; Malhotra V
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):42-8. PubMed ID: 14969836
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
11. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon.
Oliveri F; Santantonio T; Bellati G; Colombatto P; Mels GC; Carriero L; Dastoli G; Pastore G; Ideo G; Bonino F; Brunetto MR
Am J Gastroenterol; 1999 May; 94(5):1366-72. PubMed ID: 10235220
[TBL] [Abstract][Full Text] [Related]
12. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
[TBL] [Abstract][Full Text] [Related]
13. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
[TBL] [Abstract][Full Text] [Related]
14. [Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial].
Rolachon A; Kézachian G; Causse X; Baud M; Leroy V; Maynard-Muet M; Pasquier D; Zarski JP
Gastroenterol Clin Biol; 1997; 21(12):924-8. PubMed ID: 9587555
[TBL] [Abstract][Full Text] [Related]
15. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group.
Chemello L; Bonetti P; Cavalletto L; Talato F; Donadon V; Casarin P; Belussi F; Frezza M; Noventa F; Pontisso P
Hepatology; 1995 Sep; 22(3):700-6. PubMed ID: 7657272
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
[TBL] [Abstract][Full Text] [Related]
18. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study.
Ascione A; De Luca M; Canestrini C; Di Costanzo GG; Raimondo G; Longo G; Manns MP; Tillmann HL; Forte GB; Rocco P; Biceglia O; Faleo D; Vinelli F; Cela EM; Amitrano L; Addario L; Gigliotti T
Ital J Gastroenterol Hepatol; 1998 Oct; 30(5):517-23. PubMed ID: 9836109
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
